This is the one you never want to write. IO Biotech — the Copenhagen-based cancer vaccine company that held an FDA Breakthrough Therapy Designation, ran a Phase 3 trial alongside Merck, and landed on Fast Company’s Most Innovative Companies list — has filed for bankruptcy and ceased all operations. Leadership dissolved. Board dissolved. Lights off.
The proximate cause: an FDA refusal that derailed the company’s clinical programs. The specific details of which drug or designation was refused haven’t been fully detailed, but the trajectory tells you everything. IO Biotech was exploring strategic alternatives — including a potential sale — as recently as January 2026. By that point, they’d already cut staff by 50% following a cancer vaccine program setback. They were contemplating additional workforce reductions on top of that. And now… nothing. Complete dissolution.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
What makes this sting is how promising the science looked on paper. IO Biotech’s T-win platform was genuinely differentiated — it wasn’t just another checkpoint inhibitor. Cylembio (IO102-IO103) used peptide vaccines targeting IDO1 and PD-L1-expressing cells to simultaneously attack tumor cells and the immunosuppressive cells protecting them. It was off-the-shelf, subcutaneous, and designed to shift the tumor microenvironment from cold to hot. The Phase 3 trial (IOB-013/KN-D18) combined Cylembio with pembrolizumab versus pembrolizumab alone in advanced melanoma, with over 400 patients enrolled.
The investor roster wasn’t lightweight either — NOVO Holdings, RA Capital, Samsara BioCapital, VIVO Capital. The European Investment Bank kicked in up to €57.5 million in debt financing as recently as December 2024. All of that is gone now.
The cancer vaccine space is brutal. You’re competing against Moderna/Merck’s personalized mRNA approach and BioNTech/Roche’s programs, and the bar for differentiation is sky-high. IO Biotech had a real shot at something different — and a Breakthrough Therapy Designation suggested the FDA initially agreed. But regulatory biology doesn’t care about your business plan. One refusal, and the whole house of cards came down. For everyone who worked there, invested there, and enrolled in those trials — this is a terrible day.
